Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Impact of radiation target volume on health-related quality of life in patients with low grade glioma in the two-year period post treatment - XXX.

Dirven L, Reijneveld JC, Taphoorn MJB, Coens C, El-Badawy SA, Tzuk-Shina T, Bravo-Marques J, Back M, Stalpers LJA, Stupp R, Baumert BG, Seidel C.

Int J Radiat Oncol Biol Phys. 2019 Feb 1. pii: S0360-3016(19)30038-0. doi: 10.1016/j.ijrobp.2019.01.003. [Epub ahead of print]

PMID:
30716525
2.

Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.

Pe M, Dorme L, Coens C, Basch E, Calvert M, Campbell A, Cleeland C, Cocks K, Collette L, Dirven L, Dueck AC, Devlin N, Flechtner HH, Gotay C, Griebsch I, Groenvold M, King M, Koller M, Malone DC, Martinelli F, Mitchell SA, Musoro JZ, Oliver K, Piault-Louis E, Piccart M, Pimentel FL, Quinten C, Reijneveld JC, Sloan J, Velikova G, Bottomley A; Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium (SISAQOL).

Lancet Oncol. 2018 Sep;19(9):e459-e469. doi: 10.1016/S1470-2045(18)30418-2. Review.

PMID:
30191850
3.

Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review.

van der Meulen M, Dirven L, Habets EJJ, van den Bent MJ, Taphoorn MJB, Bromberg JEC.

Lancet Oncol. 2018 Aug;19(8):e407-e418. doi: 10.1016/S1470-2045(18)30356-5. Review.

PMID:
30102235
4.

The level of reporting of neurocognitive outcomes in randomised controlled trials of brain tumour patients: A systematic review.

Habets EJJ, Taphoorn MJB, Klein M, Vissers T, Dirven L.

Eur J Cancer. 2018 Sep;100:104-125. doi: 10.1016/j.ejca.2018.05.014. Epub 2018 Jul 5. Review.

PMID:
30014880
5.

The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire.

Petersen MA, Aaronson NK, Arraras JI, Chie WC, Conroy T, Costantini A, Dirven L, Fayers P, Gamper EM, Giesinger JM, Habets EJJ, Hammerlid E, Helbostad J, Hjermstad MJ, Holzner B, Johnson C, Kemmler G, King MT, Kaasa S, Loge JH, Reijneveld JC, Singer S, Taphoorn MJB, Thamsborg LH, Tomaszewski KA, Velikova G, Verdonck-de Leeuw IM, Young T, Groenvold M; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group.

Eur J Cancer. 2018 Sep;100:8-16. doi: 10.1016/j.ejca.2018.04.016. Epub 2018 Jun 21.

PMID:
29936066
6.

Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials.

Ediebah DE, Quinten C, Coens C, Ringash J, Dancey J, Zikos E, Gotay C, Brundage M, Tu D, Flechtner HH, Greimel E, Reeve BB, Taphoorn M, Reijneveld J, Dirven L, Bottomley A; Canadian Cancer Trials Group and the European Organization for Research and Treatment of Cancer.

Cancer. 2018 Aug;124(16):3409-3416. doi: 10.1002/cncr.31556. Epub 2018 Jun 15.

PMID:
29905936
7.

Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire.

van Leeuwen M, Husson O, Alberti P, Arraras JI, Chinot OL, Costantini A, Darlington AS, Dirven L, Eichler M, Hammerlid EB, Holzner B, Johnson CD, Kontogianni M, Kjær TK, Morag O, Nolte S, Nordin A, Pace A, Pinto M, Polz K, Ramage J, Reijneveld JC, Serpentini S, Tomaszewski KA, Vassiliou V, Verdonck-de Leeuw IM, Vistad I, Young TE, Aaronson NK, van de Poll-Franse LV; EORTC QLG.

Health Qual Life Outcomes. 2018 Jun 4;16(1):114. doi: 10.1186/s12955-018-0920-0.

8.

Individual changes in neurocognitive functioning and health-related quality of life in patients with brain oligometastases treated with stereotactic radiotherapy.

van der Meer PB, Habets EJJ, Wiggenraad RG, Verbeek-de Kanter A, Lycklama À Nijeholt GJ, Zwinkels H, Klein M, Dirven L, Taphoorn MJB.

J Neurooncol. 2018 Sep;139(2):359-368. doi: 10.1007/s11060-018-2868-7. Epub 2018 Apr 16.

9.

Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative.

Dirven L, Armstrong TS, Blakeley JO, Brown PD, Grant R, Jalali R, Leeper H, Mendoza T, Nayak L, Reijneveld JC, Le Rhun E, Walbert T, Weller M, Wen PY, Taphoorn MJB.

Lancet Oncol. 2018 Mar;19(3):e173-e180. doi: 10.1016/S1470-2045(18)30004-4. Review.

PMID:
29508764
10.

Clinical applicability of and changes in perfusion MR imaging in brain metastases after stereotactic radiotherapy.

Kerkhof M, Ganeff I, Wiggenraad RGJ, Lycklama À Nijeholt GJ, Hammer S, Taphoorn MJB, Dirven L, Vos MJ.

J Neurooncol. 2018 May;138(1):133-139. doi: 10.1007/s11060-018-2779-7. Epub 2018 Feb 1.

11.

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.

Taphoorn MJB, Dirven L, Kanner AA, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J, Chen TC, Sroubek J, David C, Idbaih A, Easaw JC, Kim CY, Bruna J, Hottinger AF, Kew Y, Roth P, Desai R, Villano JL, Kirson ED, Ram Z, Stupp R.

JAMA Oncol. 2018 Apr 1;4(4):495-504. doi: 10.1001/jamaoncol.2017.5082.

12.

Indicators to support healthy urban gardening in urban management.

Schram-Bijkerk D, Otte P, Dirven L, Breure AM.

Sci Total Environ. 2018 Apr 15;621:863-871. doi: 10.1016/j.scitotenv.2017.11.160. Epub 2017 Dec 18. Review.

PMID:
29216594
13.

Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).

Beier D, Proescholdt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs SE, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P.

Neuro Oncol. 2018 Feb 19;20(3):400-410. doi: 10.1093/neuonc/nox155.

14.

Visual inspection of MR relative cerebral blood volume maps has limited value for distinguishing progression from pseudoprogression in glioblastoma multiforme patients.

Kerkhof M, Tans PL, Hagenbeek RE, Lycklama À Nijeholt GJ, Holla FK, Postma TJ, Straathof CS, Dirven L, Taphoorn MJ, Vos MJ.

CNS Oncol. 2017 Oct;6(4):297-306. doi: 10.2217/cns-2017-0013. Epub 2017 Oct 6.

15.

Health-related quality of life of cranial WHO grade I meningioma patients: are current questionnaires relevant?

Zamanipoor Najafabadi AH, Peeters MCM, Lobatto DJ, Broekman MLD, Smith TR, Biermasz NR, Peerdeman SM, Peul WC, Taphoorn MJB, van Furth WR, Dirven L.

Acta Neurochir (Wien). 2017 Nov;159(11):2149-2159. doi: 10.1007/s00701-017-3332-8. Epub 2017 Sep 27. Review.

16.

Psychometric evaluation of an item bank for computerized adaptive testing of the EORTC QLQ-C30 cognitive functioning dimension in cancer patients.

Dirven L, Groenvold M, Taphoorn MJB, Conroy T, Tomaszewski KA, Young T, Petersen MA; EORTC Quality of Life Group.

Qual Life Res. 2017 Nov;26(11):2919-2929. doi: 10.1007/s11136-017-1648-8. Epub 2017 Jul 13.

17.

European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma.

Pace A, Dirven L, Koekkoek JAF, Golla H, Fleming J, Rudà R, Marosi C, Le Rhun E, Grant R, Oliver K, Oberg I, Bulbeck HJ, Rooney AG, Henriksson R, Pasman HRW, Oberndorfer S, Weller M, Taphoorn MJB; European Association of Neuro-Oncology palliative care task force.

Lancet Oncol. 2017 Jun;18(6):e330-e340. doi: 10.1016/S1470-2045(17)30345-5. Review.

18.

Development of a questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumors: a pilot study.

Oort Q, Dirven L, Meijer W, Sikkes SA, Uitdehaag BM, Reijneveld JC, Taphoorn MJ.

J Neurooncol. 2017 Mar;132(1):145-153. doi: 10.1007/s11060-016-2352-1. Epub 2017 Feb 1.

19.

Impaired health-related quality of life in meningioma patients-a systematic review.

Zamanipoor Najafabadi AH, Peeters MCM, Dirven L, Lobatto DJ, Groen JL, Broekman MLD, Peerdeman SM, Peul WC, Taphoorn MJB, van Furth WR.

Neuro Oncol. 2017 Jul 1;19(7):897-907. doi: 10.1093/neuonc/now250. Review.

20.

Advance Care Planning in Glioblastoma Patients.

Fritz L, Dirven L, Reijneveld JC, Koekkoek JA, Stiggelbout AM, Pasman HR, Taphoorn MJ.

Cancers (Basel). 2016 Nov 8;8(11). pii: E102. Review.

21.

The withdrawal of antiepileptic drugs in patients with low-grade and anaplastic glioma.

Koekkoek JA, Dirven L, Taphoorn MJ.

Expert Rev Neurother. 2017 Feb;17(2):193-202. doi: 10.1080/14737175.2016.1219250. Epub 2016 Aug 9. Review.

PMID:
27484737
22.

Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme.

Kerkhof M, Hagenbeek RE, van der Kallen BF, Lycklama À Nijeholt GJ, Dirven L, Taphoorn MJ, Vos MJ.

Eur J Neurol. 2016 Oct;23(10):1528-33. doi: 10.1111/ene.13070. Epub 2016 Jul 18.

PMID:
27424939
23.

Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial.

Akdemir G, Markusse IM, Dirven L, Riyazi N, Steup-Beekman GM, Kerstens P, Lems WF, Huizinga T, Allaart CF.

RMD Open. 2016 Mar 25;2(1):e000143. doi: 10.1136/rmdopen-2015-000143. eCollection 2016.

24.

Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial.

Markusse IM, Akdemir G, Dirven L, Goekoop-Ruiterman YP, van Groenendael JH, Han KH, Molenaar TH, Le Cessie S, Lems WF, van der Lubbe PA, Kerstens PJ, Peeters AJ, Ronday HK, de Sonnaville PB, Speyer I, Stijnen T, Ten Wolde S, Huizinga TW, Allaart CF.

Ann Intern Med. 2016 Apr 19;164(8):523-31. doi: 10.7326/M15-0919. Epub 2016 Mar 1.

PMID:
27089068
25.

Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.

Koekkoek JA, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC, Taphoorn MJ.

J Neurooncol. 2016 Jan;126(2):347-54. doi: 10.1007/s11060-015-1975-y. Epub 2015 Nov 7.

26.

Anaplastic gliomas: end-of-life care recommendations.

Dirven L, Sizoo EM, Taphoorn MJ.

CNS Oncol. 2015;4(5):357-65. doi: 10.2217/cns.15.31. Epub 2015 Oct 28. Review.

27.

Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study.

Habets EJ, Dirven L, Wiggenraad RG, Verbeek-de Kanter A, Lycklama À Nijeholt GJ, Zwinkels H, Klein M, Taphoorn MJ.

Neuro Oncol. 2016 Mar;18(3):435-44. doi: 10.1093/neuonc/nov186. Epub 2015 Sep 18.

28.

Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study.

Markusse IM, Dirven L, Gerards AH, van Groenendael JH, Ronday HK, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

Arthritis Res Ther. 2015 Aug 31;17:232. doi: 10.1186/s13075-015-0730-2.

29.

Evaluating Adherence to a Treat-to-Target Protocol in Recent-Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation.

Markusse IM, Dirven L, Han KH, Ronday HK, de Sonnaville PB, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

Arthritis Care Res (Hoboken). 2016 Apr;68(4):446-53. doi: 10.1002/acr.22681.

30.

Controversies in defining cancer survivorship.

Dirven L, van de Poll-Franse LV, Aaronson NK, Reijneveld JC.

Lancet Oncol. 2015 Jun;16(6):610-2. doi: 10.1016/S1470-2045(15)70236-6. Epub 2015 May 27. No abstract available.

PMID:
26065599
31.
32.

The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.

Dirven L, van den Bent MJ, Bottomley A, van der Meer N, van der Holt B, Vos MJ, Walenkamp AM, Beerepoot LV, Hanse MC, Reijneveld JC, Otten A, de Vos FY, Smits M, Bromberg JE, Taal W, Taphoorn MJ; Dutch Neuro-Oncology Group (LWNO).

Eur J Cancer. 2015 Jul;51(10):1321-30. doi: 10.1016/j.ejca.2015.03.025. Epub 2015 Apr 17.

PMID:
25899986
33.

Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review.

Koekkoek JA, Kerkhof M, Dirven L, Heimans JJ, Reijneveld JC, Taphoorn MJ.

Neuro Oncol. 2015 Jul;17(7):924-34. doi: 10.1093/neuonc/nov032. Epub 2015 Mar 25. Review.

34.

Continued participation in a ten-year tight control treat-to-target study in rheumatoid arthritis: why keep patients doing their best?

Markusse IM, Dirven L, Han KH, Ronday HK, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

Arthritis Care Res (Hoboken). 2015 May;67(6):739-45. doi: 10.1002/acr.22540.

35.

Joint modeling of longitudinal health-related quality of life data and survival.

Ediebah DE, Galindo-Garre F, Uitdehaag BM, Ringash J, Reijneveld JC, Dirven L, Zikos E, Coens C, van den Bent MJ, Bottomley A, Taphoorn MJ.

Qual Life Res. 2015 Apr;24(4):795-804. doi: 10.1007/s11136-014-0821-6. Epub 2014 Oct 14.

PMID:
25311306
36.

Health-related quality of life or quantity of life: a difficult trade-off in primary brain tumors?

Dirven L, Reijneveld JC, Taphoorn MJB.

Semin Oncol. 2014 Aug;41(4):541-552. doi: 10.1053/j.seminoncol.2014.06.002. Epub 2014 Jun 11. Review.

PMID:
25173146
37.

Symptoms and medication management in the end of life phase of high-grade glioma patients.

Koekkoek JA, Dirven L, Sizoo EM, Pasman HR, Heimans JJ, Postma TJ, Deliens L, Grant R, McNamara S, Stockhammer G, Medicus E, Taphoorn MJ, Reijneveld JC.

J Neurooncol. 2014 Dec;120(3):589-95. doi: 10.1007/s11060-014-1591-2. Epub 2014 Aug 24.

PMID:
25151506
38.

A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study.

Markusse IM, Dirven L, van den Broek M, Bijkerk C, Han KH, Ronday HK, Bolce R, Sasso EH, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

J Rheumatol. 2014 Nov;41(11):2114-9. doi: 10.3899/jrheum.131412. Epub 2014 Aug 15.

39.

Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: design of a prospective observational study.

Koekkoek JA, Kerkhof M, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Bromberg JE, van den Bent MJ, Reijneveld JC, Taphoorn MJ.

BMC Neurol. 2014 Aug 15;14:157. doi: 10.1186/s12883-014-0157-4.

40.

Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.

Koekkoek JA, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC, Taphoorn MJ.

J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):366-73. doi: 10.1136/jnnp-2014-308136. Epub 2014 Jul 23.

PMID:
25055819
41.

End of life care in high-grade glioma patients in three European countries: a comparative study.

Koekkoek JA, Dirven L, Reijneveld JC, Sizoo EM, Pasman HR, Postma TJ, Deliens L, Grant R, McNamara S, Grisold W, Medicus E, Stockhammer G, Oberndorfer S, Flechl B, Marosi C, Taphoorn MJ, Heimans JJ.

J Neurooncol. 2014 Nov;120(2):303-10. doi: 10.1007/s11060-014-1548-5. Epub 2014 Jul 20.

PMID:
25038849
42.

The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: a systematic review.

Dirven L, Taphoorn MJ, Reijneveld JC, Blazeby J, Jacobs M, Pusic A, La Sala E, Stupp R, Fayers P, Efficace F; EORTC Quality of Life Group (Patient Reported Outcome Measurements Over Time In ONcology-PROMOTION Registry).

Eur J Cancer. 2014 Sep;50(14):2432-48. doi: 10.1016/j.ejca.2014.06.016. Epub 2014 Jul 14. Review.

PMID:
25034656
43.

Intra articular injection with corticosteroids in patients with recent onset rheumatoid arthritis: subanalyses from the BeSt study.

Gvozdenović E, Dirven L, van den Broek M, Han KH, Molenaar ET, Landewé RB, Lems WF, Allaart CF.

Clin Rheumatol. 2014 Feb;33(2):263-7. doi: 10.1007/s10067-013-2465-2. Epub 2014 Jan 3.

PMID:
24384824
44.

Health-related quality of life in high-grade glioma patients.

Dirven L, Aaronson NK, Heimans JJ, Taphoorn MJ.

Chin J Cancer. 2014 Jan;33(1):40-5. doi: 10.5732/cjc.013.10214. Review.

45.

The end-of-life phase of high-grade glioma patients: a systematic review.

Sizoo EM, Pasman HR, Dirven L, Marosi C, Grisold W, Stockhammer G, Egeter J, Grant R, Chang S, Heimans JJ, Deliens L, Reijneveld JC, Taphoorn MJ.

Support Care Cancer. 2014 Mar;22(3):847-57. doi: 10.1007/s00520-013-2088-9. Epub 2013 Dec 14. Review.

PMID:
24337718
46.

Measuring health-related quality of life in high-grade glioma patients at the end of life using a proxy-reported retrospective questionnaire.

Sizoo EM, Dirven L, Reijneveld JC, Postma TJ, Heimans JJ, Deliens L, Pasman HR, Taphoorn MJ.

J Neurooncol. 2014 Jan;116(2):283-90. doi: 10.1007/s11060-013-1289-x. Epub 2013 Oct 29.

PMID:
24162875
47.

Health-related quality of life in patients with brain tumors: limitations and additional outcome measures.

Dirven L, Reijneveld JC, Aaronson NK, Bottomley A, Uitdehaag BM, Taphoorn MJ.

Curr Neurol Neurosci Rep. 2013 Jul;13(7):359. doi: 10.1007/s11910-013-0359-y. Review.

PMID:
23666388
48.

Early local swelling and tenderness are associated with large-joint damage after 8 years of treatment to target in patients with recent-onset rheumatoid arthritis.

van den Broek M, Dirven L, Kroon HM, Kloppenburg M, Ronday HK, Peeters AJ, Kerstens PJ, Huizinga TW, Lems WF, Allaart CF.

J Rheumatol. 2013 May;40(5):624-9. doi: 10.3899/jrheum.121248. Epub 2013 Apr 1.

PMID:
23547212
49.

A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study.

Hirata S, Dirven L, Shen Y, Centola M, Cavet G, Lems WF, Tanaka Y, Huizinga TW, Allaart CF.

Rheumatology (Oxford). 2013 Jul;52(7):1202-7. doi: 10.1093/rheumatology/kes362. Epub 2013 Feb 7.

50.

Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy.

Dirven L, Klarenbeek NB, van den Broek M, van Groenendael JH, de Sonnaville PB, Kerstens PJ, Huizinga TW, Dijkmans BA, Lems WF, Allaart CF.

Clin Rheumatol. 2013 May;32(5):585-90. doi: 10.1007/s10067-012-2136-8. Epub 2012 Dec 9.

PMID:
23224330

Supplemental Content

Loading ...
Support Center